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Abstract 
Background: Metastatic uveal melanoma is a highly fatal disease; most patients die from their hepatic metastasis 
within 1 year. A major drawback in the development of new treatments for metastatic uveal melanoma is the dif-
ficulty in obtaining appropriate cell lines and the lack of appropriate animal models. Patient-derived xenograft (PDX) 
tumor models, bearing ectopically implanted tumors at a subcutaneous site, have been developed. However, these 
ectopically implanted PDX models have obstacles to translational research, including a low engraftment rate, slow 
tumor growth, and biological changes after multiple passages due to the different microenvironment. To overcome 
these limitations, we developed a new method to directly transplant biopsy specimens to the liver of immunocom-
promised mice.
Results: By using two metastatic uveal melanoma cell lines, we demonstrated that the liver provides a more suit-
able microenvironment for tumor growth compared to subcutaneous sites and that surgical orthotopic implanta-
tion (SOI) of tumor pieces allows the creation of a liver tumor in immunocompromised mice. Subsequently, 10 of 
12 hepatic metastasis specimens from patients were successfully xenografted into the immunocompromised mice 
(83.3% success rate) using SOI, including 8 of 10 needle biopsy specimens (80%). Additionally, four cryopreserved PDX 
tumors were re-implanted to new mice and re-establishment of PDX tumors was confirmed in all four mice. The seri-
ally passaged xenograft tumors as well as the re-implanted tumors after cryopreservation were similar to the original 
patient tumors in histologic, genomic, and proteomic expression profiles. CT imaging was effective for detecting and 
monitoring PDX tumors in the liver of living mice. The expression of Ki67 in original patient tumors was a predictive 
factor for implanted tumor growth and the success of serial passages in PDX mice.
Conclusions: Surgical orthotopic implantation of hepatic metastasis from uveal melanoma is highly successful in the 
establishment of orthotopic PDX models, enhancing their practical utility for research applications. By using CT scan, 
tumor growth can be monitored, which is beneficial to evaluate treatment effects in interventional studies.
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Background
Uveal melanoma, which originates from the iris, cili-
ary body, or choroid, is highly fatal when it metasta-
sizes. The mortality rate is over 90% within 2  years of 
initial diagnosis of metastasis, and median survival time 
ranges from 6  months to 1  year [1, 2]. Approximately 
90% of metastatic uveal melanoma deaths are attributed 
to hepatic metastasis [2, 3]. Patients who first develop 
intra-hepatic metastasis have a shorter survival time than 
those who instead first develop extra-hepatic metastasis 
[4]. The major drawback in the development of new treat-
ments for metastatic uveal melanoma is difficulty obtain-
ing appropriate cell lines and animal models. In general, 
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metastatic UM cell lines are very difficult to establish, 
and less than 20 metastatic uveal melanoma cell lines are 
currently available in the world. Furthermore, there are 
only a limited number of pre-clinical models using met-
astatic uveal melanoma to test the efficacy of a specific 
treatment. Currently available in vivo assays are either a 
subcutaneous injection of cell lines derived from uveal 
melanoma or retro-orbital injection of liver-selected 
murine cutaneous melanoma B16 cells [5, 6]. Given that 
uveal melanoma metastases typically colonize the liver 
and the genetics of uveal melanoma contrasts with that 
of cutaneous melanoma, there is a clear need to develop 
more biologically relevant in  vivo models to test thera-
peutic strategies in advanced-stage uveal melanoma.
Patient-derived xenograft (PDX) tumor models, bear-
ing implanted tumors from patients, were developed to 
meet the demands of precision medicine. A PDX mouse 
model holds promise because it offers a personalized 
treatment approach and may be useful to predict clini-
cal prognosis, drug efficacy, and tumor characteristics 
[7]. Most PDX models, including previously reported 
uveal melanoma PDX models, are made by ectopic sub-
cutaneous implantation due to the ease of this implan-
tation technique [8, 9]. However, subcutaneous PDX 
models present fundamental limitations for translational 
research due to differences in the anatomic microen-
vironment from the hepatic site of tumor origin, low 
engraftment rate, and slow tumor growth [10–15]. Ide-
ally, patient tumors should be implanted orthotopically 
into the same organ from which they were removed 
[16]. In the case of metastatic uveal melanoma, this is an 
orthotopic liver tumor xenograft model.
Orthotopic liver tumor xenograft mouse models were 
first described more than 2  decades ago [17]; however, 
these mouse models have not been well utilized due to 
technically demanding procedures for the establishment. 
The conventional implantation technique [18, 19] is com-
plicated and requires the use of specialized equipment, 
including 6-0 to 8-0 fine suture under a microscope. 
Tumor and normal liver tissue must be sutured carefully 
so that the suture does not injure the fragile liver tissue 
and lead to hematoma [20]. To circumvent these techni-
cal difficulties, we developed a novel surgical orthotopic 
implantation (SOI) technique in which a pocket is made 
in the liver parenchyma to houses the tumor entirely 
within the parenchyma (liver pocket method), followed 
by the closure of incision site with absorbable hemostatic 
materials, instead of the suture. Our method provides an 
optimal microenvironment for tumor development in the 
liver and it is especially suitable for hepatic metastasis 
from primary uveal melanoma.
As described above, the main purpose of this study is to 
circumvent the limitations of conventional PDX models 
that use subcutaneous implantation by developing an 
appropriate orthotopic hepatic PDX model of metastatic 
uveal melanoma in the NOD.Cg-Prkdcscid  Il2rgtm1Wjl/SzJ 
(NSG) mouse. To develop orthotopic hepatic transplant 
models, we first compared the differences in tumor cell 
growth in a liver site versus a subcutaneous site using 
two metastatic uveal melanoma cell lines, to ascertain 
which site provides a more suitable tumor microenvi-
ronment for the tumor growth. Then, the feasibility of 
SOI of tumor tissues (liver pocket method) was inves-
tigated to develop a practical liver tumor xenograft 
mouse model for metastatic uveal melanoma. Finally, by 
using this method, we attempted to establish orthotopic 
PDX mouse models from hepatic metastasis samples 
from 12 different uveal melanoma patients. We evalu-
ated concordance for tumor characteristics between 
pre-implanted and post-implanted tumors. To our 
knowledge, our study is the first demonstration of an 
orthotopic hepatic PDX transplant model for metastatic 
uveal melanoma.
Results
Liver is a suitable microenvironment to support growth 
of metastatic uveal melanoma cell lines
To compare growth characteristics of human uveal mela-
noma cells at hepatic and subcutaneous xenograft sites in 
the mouse, TJU-UM001 and TJU-UM004 single cell sus-
pensions were injected at 1 × 106 cells into the liver and 
the subcutaneous site, respectively (Fig.  1). At 8  weeks 
after injection, UM001 tumors were confirmed to be 
engrafted in the liver in three mice (Table  1). In con-
trast, the subcutaneous site did not engraft the UM001 
tumors, although mice were observed for up to 12 weeks 
after injection. UM004 tumors grew at both the liver and 
subcutaneous sites; however, UM004 tumors were sig-
nificantly larger in the liver than the subcutaneous site at 
4  weeks after injection. To re-examine whether UM001 
cells can grow at the subcutaneous site, three different 
cell titers (2, 5, and 10 × 106 cells) of UM001 cells were 
injected, but UM001 tumors did not form by 12  weeks 
post injection. Only the cicatrix of a tumor was found 
at 12  weeks when a higher number of tumor cells was 
injected into the subcutaneous site. These findings indi-
cate that compared to the subcutaneous site, the liver 
offers a more suitable microenvironment to grow the 
metastatic uveal melanoma cell lines.
Surgical orthotopic implantation (SOI) using the liver 
pocket method generates a liver tumor xenograft model
To develop a practical liver tumor xenograft model, a 
novel procedure for SOI of the tumor piece (liver pocket 
method) was developed. Donor tumors, which were gen-
erated in mouse host livers by injecting uveal melanoma 
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Fig. 1 a Schematic overview of liver and subcutaneous tumor implantation by needle injection using established cell lines. For mice injected with 
tumor suspensions into the liver, tumor volume was measured at sacrifice. Liver UM001 tumor-bearing mice were sacrificed at 8 weeks and UM004 
tumor-bearing mice were sacrificed at 4 weeks post-injection. For mice injected with tumor suspensions at the subcutaneous site, tumor volume 
was measured three times (4, 8, and 12 weeks) before the mice were sacrificed at 12 weeks post-injection. b–p Macroscopic, histopathological, and 
radiological features of liver and subcutaneous tumors generated with established cell lines. b, j Laparotomy image. c, h, k, p Macroscopic findings 
for resected tumors. d, l Cut surface of the tumor. e, m Sagittal imaging using CT, black arrows indicate tumors. f, n H&E staining, ×10, Scale bar 
1 mm. g, o Macroscopic findings for subcutaneously injected sites. i H&E staining, ×400, Scale bar 50 µm. SC subcutaneous site
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cell lines, were surgically transplanted into the livers of 
recipient mice (Fig.  2). This new SOI with liver pocket 
method was successfully performed on all 20 recipient 
mice, with ten receiving UM001 tumor pieces and ten 
receiving UM004 tumor pieces (Additional file  1: Table 
S1). Median operation time was 22  min, and median 
blood loss during the operation was 0.13  g. Adverse 
events, such as hematoma, bile leakage, and tumor devia-
tion, did not occur in any of the 20 mice. Half of the 20 
mice were sacrificed at day 1 post-implantation (5 UM001 
mice and 5 UM004 mice). An autopsy confirmed that 
tumors remained localized in the parenchyma of the liver 
without any tumor deviation in these ten mice (Fig.  2). 
The remaining ten mice were sacrificed later (five UM001 
mice at 8 weeks post-implantation and five UM004 mice 
at 4  weeks post-implantation). For comparison with the 
liver implanted tumors, tumor pieces generated from the 
uveal melanoma cell lines were also implanted at the same 
time into the subcutaneous site in ten additional mice 
(five mice for UM001 and five mice for UM004).
As shown in Table  1 and Additional file  2: Figure S1, 
all recipient mice in which tumor pieces were directly 
transplanted into the liver using the liver pocket method 
developed tumors in their liver. By comparison, the mice 
in which tumor pieces were implanted subcutaneously 
exhibited much smaller tumors at the same respective 
time points. Neither of the mouse groups developed 
tumors anywhere except at the implanted sites. The ratio 
of Ki67-positive cells was higher in the liver tumors than 
in the subcutaneous tumors for both cell lines tested 
(UM001 recipient liver vs. recipient subcutaneous site, 
p < 0.001; UM004 recipient liver vs. recipient subcutane-
ous site, p < 0.001) (Table 1).
Concordance for tumor characteristics between donor 
and recipient tumors in the liver
The expression of three different melanoma markers 
(HMB45, MelanA, and S100) and a cell proliferation 
marker (Ki67) was similar between donor and recipient 
tumors generated from the UM001 and UM004 cell lines 
(Additional file 3: Figure S2a). The ratio of Ki67-positive 
cells in the liver was transiently decreased at 1 day post-
implantation; however, the ratio of Ki67-positive cells 
was similar between donor and established recipient liver 
tumors (UM001 donor liver vs. recipient liver, p = 0.785; 
UM004 donor liver vs. recipient liver, p  =  0.786) 
(Table  1). By reverse phase protein array (RPPA) analy-
sis, both donor and recipient liver tumors showed highly 
matching tumor characteristics with respect to pro-
tein expression, yielding Pearson correlation analysis 
results of  r2 = 0.9559, p < 0.001 for UM001 tumors and 
 r2  =  0.8741, p  <  0.001 for UM004 tumors, respectively 
(Additional file 3: Figure S2b, c).
Establishment of an orthotopic patient-derived liver 
metastatic uveal melanoma xenograft model
After establishing the SOI method in NSG mice, we 
investigated whether an orthotopic PDX mouse model 
can be established using hepatic metastasis specimens 
from actual uveal melanoma patients. Patient-derived 
tumor specimens were obtained by core biopsy (n = 10) 
or surgery (n  =  2) from 12 uveal melanoma patients 
with hepatic metastasis. These patient-derived tumor 
specimens were implanted to the liver of NSG mice, 
and the NSG mice were observed up to six months. All 
mice were sacrificed at 6  months post-tumor implanta-
tion after contrast-enhanced CT imaging evaluation. As 
shown in Table 2; Fig. 3a–h and Additional file 4: Figure 
S3, 10 PDXs were established successfully from the 12 
patients (engraftment rate 83.3%) within 6 months. Over-
all, tumors were confirmed in 18 of 27 implanted mice 
(66.7%). The presence of tumors was confirmed by con-
trast enhanced CT imaging in all cases. It is of note that 
needle biopsy specimens successfully engrafted in 8 of 10 
patients (80%). Since hepatic metastasis tends to develop 
in both lobes of the liver, surgical removal of the tumor is 
not a feasible option for the majority of patients. In this 
regard, the successful PDX tumor establishment from 
core biopsy specimens is highly encouraging.
To maintain PDX tumors in NSG mice, tumors 
obtained from the first generation of mice (X1) were seri-
ally transplanted to the next cohorts of mice (X2 and X3). 
All 10 xenograft tumors were successfully transplanted 
into second-generation mice (X2). We were able to seri-
ally passage 6 of 10 PDX tumors and engraft them into 
third-generation mice (X3). By examining the expression 
profiles of the original patient tumors, we found that high 
expression of Ki67 was a predictive factor for their abil-
ity to undergo serial passaging and successful engraft-
ment into the third-generation mice (p < 0.05) (Table 3). 
The ratio of Ki67-positive cells in original patient tumors 
correlated significantly with median tumor volume in 
first-generation mice (Pearson correlation analysis of 
 r2  =  0.699, p  <  0.01; Fig.  3i). Collectively, these results 
indicate that high expression of Ki67 in parental tumors 
confers enhanced tumor growth and successful serial 
passages in PDX mice.
Reimplantation of cryopreserved tumors
After successful engraftment of patient-derived xenograft 
tumors in first-generation mice (X1), three 1-mm cubes of 
chunks from individual PDX tumors obtained from cases 
2, 5, 7, and 12 were cryopreserved in liquid nitrogen using 
three different cryopreservation media (F, D, R medium 
respectively). After cryopreservation, these cryopreserved 
PDX tumor specimens were re-implanted. All cryo-
preserved PDX tumor chunks except one in F medium 
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from case 7 were successfully engrafted into the livers of 
recipient mice, as were freshly transplanted tumor pieces 
without cryopreservation (Table  4). Tumor volumes of 
the cryopreserved tumors were smaller than those of the 
directly transplanted tumors when they were sacrificed at 
6  months after tumor transplantation. Among the three 
Fig. 2 a Schematic overview of the surgical implantation of tumor pieces into the liver and a subcutaneous site. Tumor mass was generated in 
donor mice following injection of UM001 and UM004 cell lines to the liver, as described in Fig. 1a. Tumor mass was harvested from the donor mouse 
and cut into 1 mm cubes. These small tumor pieces were transplanted into the liver or a subcutaneous site of recipient mice. UM001- and UM004-
derived tumor pieces were separately implanted into the liver in 10 mice for each cell line. Five mice were sacrificed at 1 day after implantation. The 
remaining five mice were sacrificed at 8 weeks after implantation for UM001, or 4 weeks after implantation for UM004, respectively. Furthermore, 
UM001- and UM004-derived tumor pieces were also separately implanted into the subcutaneous site in five mice for each cell line. The five mice 
were sacrificed at the same time points as the liver tumor-bearing mice. b–i Histopathological features of implanted tumors in the liver at 1 day 
post implantation using established cell lines. b, f Laparotomy image. c, g Macroscopic findings for resected tumor. d, h Cut surface of the tumor. e, 
i H&E staining, ×40, Scale bar 500 µm
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freezing methods tested, Cryomedium D (DMEM con-
taining medium) resulted in the highest growth rates fol-
lowing thawing and re-implantation of the frozen tumor 
samples. Despite the slower growth of the cryopreserved 
tumor specimens, the ratio of Ki67-positive cells in the 
cryopreserved tumors was similar to that of the directly 
transplanted tumors. From these studies, we conclude that 
while cryopreserved tumors can be successfully engrafted 
in mice, the growth of cryopreserved tumor samples is 
reduced compared to the directly transplanted, non-frozen 
tumor samples. Considering comparative Ki67 activity in 
established PDX tumor specimens in X2 mice, this is most 
likely due to loss of a fraction of proliferative tumor cells in 
the cryopreserved tumor chunks.
Fig. 3 a–h Two representative examples of the histopathological and radiological features of the uveal melanoma PDX models. a, c Laparotomy. b, 
d Macroscopic findings for resected liver, showing left lobe with tumor. e, g Axial imaging on CT. f, h Sagittal imaging on CT. Black arrows indicate 
patient-derived xenograft tumors. i Correlation between the ratio of Ki67-positive cells in original patient tumors and median tumor volume in first-
generation mice bearing the corresponding patient-derived tumors. y = 0.1054x + 0.725, r = 0.836,  r2 = 0.699, p < 0.01. Linear scale is converted to 
logarithmic scale for tumor volume
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Xenograft tumors histologically resemble the original 
hepatic metastasis obtained from patients
Hematoxylin and eosin (H&E) staining revealed a strong 
concordance between the histopathological features of 
the patient tumors and their corresponding xenograft 
tumors in mice (Fig. 4a and Additional file 5: Figure S4). 
Xenograft tumors retained a similar degree of pigmenta-
tion as observed in the original patient tumors (Table 2). 
Serially passaged xenograft tumors also retained the 
same morphology and pigmentation as their original 
patient tumors. The three melanoma markers (HMB-45, 
Melan-A, and S100) were expressed at similar relative 
levels in patient tumors and their corresponding xeno-
graft tumors. Furthermore, the ratio of Ki67-positive 
cells in the original tumors was also akin to that in the 
corresponding xenograft tumors.
Xenograft tumors retain mutations present in their 
parental patient tumors
We identified five representative mutations in uveal mel-
anoma. In 10 out of 12 samples available for mutation 
analysis, the xenograft tumors contained the exact same 
mutations as their corresponding original patient tumors. 
An exception was observed for case 11 at the EIF1AX 
locus (Table 2). The mutation rate for five representative 
mutations was 40, 30, 50, 20, and 10% in GNAQ, GNA11, 
BAP1, SF3B1, and EIF1AX, respectively. Mutations in 
GNAQ and GNA11 were mutually exclusive, as were 
mutations in BAP1, SF3B1, and EIF1AX with each other. 
For PDX cases 2, 5 and 12, a total of nine tumor samples 
re-implanted after cryopreservation also retained the 
same mutational profiles as their corresponding original 
patient tumors.
Xenograft tumors preserve the DNA copy number 
alterations in their original patient tumors
The patterns of copy number variations (CNVs) in the 
original patient tumors are mostly maintained in the cor-
responding first-, second-, and third-generation xenograft 
tumors, as well as in tumors generated by re-implantation 
of cryopreserved samples (Fig.  4b; Additional file  6: Fig-
ure S5). CNVs in tumors displayed representative charac-
teristics of uveal melanoma cells, including monosomy 3 
accompanied by chromosome 1p loss, 8q gain, and 8p loss. 
In particular, the 8q gain was observed in all 12 cases, as 
was c-myc amplification in 8q. For cases 8 and 11, CNVs 
in patient tumors did not match the corresponding original 
tumors. These patient tumors showed a normal pattern of 
CNVs because of the very small volumes of tumor in the 
biopsy specimen, whereas the xenograft tumors displayed 
Table 3 Predictive factors for successful engraftment of PDX tumor
Large 4 copies, Small 3 copies or partial 4 copies
Engraftment 
of 1st-genera-
tion mice  (X1)
p value Achievement 
of serial pas-
sages to 3rd-
generation mice 
 (X3)
p value Engraftment 
of 1st-genera-
tion mice  (X1)
p value Achievement 
of serial pas-
sages to 3rd-
generation mice 
 (X3)
p value
Success Failure Success Failure Success Failure Success Failure
Patient gender n = 12 n = 12 c-myc gain n = 10 n = 10
 Male 5 1 1.00 3 3 1.00  High gain 6 1 1.00 5 2 0.500
 Female 5 1 3 3  Low gain 2 1 1 2
Age n = 12 n = 12 GNAQ n = 10 n = 10
 ≥60 4 2 0.454 2 4 0.567  Positive 4 0 1.00 3 1 0.571
 <60 6 0 4 2  Negative 5 1 3 3
Tumor sample n = 12 n = 12 GNA11 n = 10 n = 10
 Surgery 2 0 1.00 1 1 1.00  Positive 3 0 1.00 2 1 1.00
 Biopsy 8 2 5 5  Negative 6 1 4 3
Pigmentation n = 12 n = 12 BAP1 n = 10 n = 10
 None 4 1 1.00 3 2 1.00  Positive 5 0 1.00 4 1 0.528
 Pigments 6 1 3 4  Negative 4 1 2 3
Ki67 (%) n = 11 n = 11 SF3B1 n = 10 n = 10
 ≥10 6 0 0.455 6 0 0.002  Positive 1 1 0.200 0 2 0.133
 <10 4 1 0 5  Negative 8 0 6 2
Monosomy 3 n = 10 n = 10 EIF1AX n = 10 n = 10
 Positive 7 1 0.378 6 2 0.133  Positive 0 0 1.00 0 0 1.00
 Negative 1 1 0 2  Negative 9 1 6 4
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Fig. 4 a Two representative examples of histopathological features of patient tumors and the corresponding xenograft tumors. H&E-stained sec-
tions and immunostained sections with HMB-45, Melan A, and S-100 antibodies, ×400. Scale bar 50 µm. Patient tumors are depicted in the columns 
1 and 4. The corresponding xenograft tumors are depicted in columns 2 and 3, and 5 and 6, respectively. Control panels show no positive signal with 
an isotype control antibody (inset images located at bottom right in each immunostaining panel). X0 Patient original tumors, X1 PDX tumors in the 
first-generation mice, X2 PDX tumors in the second-generation mice. b Two representative examples of DNA copy number variation with karyo-
gram. Individual chromosomes are shown in the karyograms, with bars on the right side of the karyograms indicating the chromosomal locations 
of copy number losses and gains, respectively. Chromosomes 1 to 12 are lined up on the top and chromosome 13 to 22, X and Y are on the bottom. 
From left to right, patient tumor  (X0) is at the left with its adjacent karyogram, the corresponding first-generation xenograft tumor  (X1) is in the sec-
ond column, the corresponding second-generation xenograft  (X2) is in the third column, and three different xenograft tumors generated from frozen 
tumor specimens using F, D and R cryopreservation medium are in the fourth to sixth columns. A copy number of 2 (normal) is indicated by blank 
space (no color); copy number greater than 2 (chromosomal gain or amplification) is indicated in blue; and copy number less than 2 (chromosomal 
loss or deletion) is indicated in red
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a typical pattern of uveal melanoma CNVs. Unsupervised 
hierarchical clustering using patterns of CNV revealed that 
patient tumors clustered with the corresponding xenograft 
tumors and the corresponding cryopreserved tumors in 10 
successful engraftment cases (Fig. 5a).
Stability of xenograft tumors on their proteome 
as determined by reverse phase protein array (RPPA)
We performed RPPA on nine paired original patient 
tumors and the corresponding xenograft tumors for ten 
successful engraftment cases (excluding case 11 due to 
unavailability of tumor samples). The related samples 
clustered together regarding their protein expression 
profiling, thus demonstrating stability at the level of the 
proteome between the original patient tumors and their 
subsequently derived PDX tumors (Fig. 5b).
Discussion
To generate PDX mouse models, the ectopic subcuta-
neous implantation method has been used due to quick 
implantation of tumors and ease of monitoring [8]. 
However, orthotopic engraftment of the tumor is more 
rational for a PDX model because tumor cells reside in 
the similar microenvironment as the original tumor [21, 
22]. For example, orthotopic soft-tissue sarcoma xeno-
grafts retained the same morphology as primary tumors, 
whereas ectopically implanted xenograft tumors altered 
their morphology due to the influence of the tumor 
microenvironment [23]. Orthotopic breast tumor xeno-
grafts were considered to be more accurate models for 
tumor microenvironment and clinical cancer progres-
sion compared with the subcutaneous xenografts [24]. 
Similarly, lung and colon cancer xenograft mouse models 
respond differently to chemotherapy, depending on the 
sites of transplantation [25, 26]. Collectively, these stud-
ies indicate that patient-derived orthotopic xenograft 
(PDOX) tumor models mirror the corresponding patient 
tumors more accurately than models using ectopic 
implantation sites [16].
Our liver pocket method makes surgical orthotopic 
implantation (SOI) in the liver simpler than the conven-
tional techniques, allowing us to finish implantation of 
Fig. 5 a Unsupervised hierarchical clustering of paired patient tumors and xenograft tumors based on DNA copy number analysis. X0 Patient origi-
nal tumors, X1 PDX tumors in the first-generation mice, X2 PDX tumors in the second-generation mice, F F medium (90% fetal bovine serum/10% 
DMSO), D D medium (70% DMEM/20% fetal bovine serum/10% DMSO); R R medium (70% RPMI/20% fetal bovine serum/10% DMSO). b Unsuper-
vised hierarchical clustering of paired patient tumors and xenograft tumors based on reverse phase protein array (RPPA) analysis
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patient tumor tissues into the liver in less than 5  min, 
most of which time is required for closing the abdo-
men with a double-layer suture. Absorbable hemo-
static material plays a major role in sealing the incision 
and preventing bleeding. Average bleeding volume was 
approximately less than 10% of circulating blood volume 
in mice [27]. Because the hemostatic materials prevented 
surgical bleeding, we were able to operate with greater 
confidence and achieve excellent survival outcomes for 
our PDX mouse models without treatment-related death.
Although PDX models have proven to be useful for 
cancer research, there are still some obstacles to their 
use in translational research [7, 28, 29]. First, engraft-
ment failure occurs at a high rate for some tumors, 
including subcutaneous implantation of uveal melanoma 
[9, 13, 14]. It is essential to improve tumor engraftment 
so that a larger number of PDX models can be success-
fully generated, enabling them to be effectively utilized 
for tumor data profiling and mouse drug efficacy trials, 
and avoiding selection bias of PDX models due to poor 
engraftment rate. In our study, we found that the ortho-
topic hepatic implantation technique enhanced the rate 
of tumor engraftment of metastatic uveal melanoma, 
compared to subcutaneous implantation with uveal mel-
anoma metastases [9]. Additionally, most PDX studies 
have required surgically harvested tumor materials, not 
needle biopsy specimens [7] to obtain sufficient amounts 
of tumor specimens from patients. Engraftment failure is 
commonly encountered in core biopsy samples contain-
ing fewer tumor cells. In this regard, the high success rate 
of engraftment in our method is encouraging and sug-
gests that core biopsy specimens can be used effectively 
to generate PDX models by orthotopic implantation.
One of the disadvantages of PDX models for drug 
screening is the discrepancy between engraftment time 
in mice and imminent treatment schedules for patients, 
which limits timely personalized pre-clinical drug tri-
als using PDX models [7, 28]. Our study harvested the 
tumors in less than 6 months post-implantation, which is 
shorter than the time required for tumor establishment in 
subcutaneous implantation models; however, additional 
time is still needed to generate second- or third-genera-
tion PDX mouse models for personalized drug trials. We 
plan to investigate whether we can develop PDX tumors 
from primary uveal melanoma. If this approach is suc-
cessful, we might be able to develop PDX tumor models 
from individual patients before these patients develop 
actual systemic recurrence, which would help patients 
select the most appropriate course of treatment.
It has been reported that serial transplantation of tumors 
to recipient mice causes genetic drift [30, 31]. In general, 
multiple passages of PDX models or changing the site of 
implantation are not recommended to preserve the genetic 
and proteomic consistency of the original patient tumor. 
Serial passages might cause genomic rearrangements 
intrinsic to tumor adaptation [28]. This is a serious con-
cern to use uveal melanoma cell lines established from PDX 
tumors for the purpose of pre-clinical drug screening to 
design early phase clinical trials. To minimize genetic and 
proteomic alterations, we orthotopically implanted liver 
tumors into the equivalent organ in mice. In 10 success-
ful cases, both the original tumors and the corresponding 
xenograft tumors show the same tissue histologic features 
in H&E staining and immunohistochemistry, mutations 
and CNV in genomic analyses, and RPPA in proteomic 
analyses. Therefore, SOI with hepatic metastasis is a reli-
able method to create PDX mouse models that retain the 
characteristics of original patient tumors. Furthermore, it 
is preferable to restrict PDX models to a low passage num-
ber to maintain tumor characteristics of the original tumor 
[31]. In this regard, biobanking of PDX tumors will be criti-
cal to store patient tumors and their corresponding xeno-
graft tumors for re-implantation when required [32]. Our 
preliminary studies indicate that re-implantation of cryo-
preserved tumors is feasible without changing the charac-
teristics of PDX tumors. This cryopreservation approach 
will facilitate the expansion of our PDX platform for large-
scale pre-clinical drug screening using PDX tumors.
Cytogenetic investigations have revealed that most 
uveal melanomas have abnormal chromosomes 1, 3, 6 
and 8 [33, 34]. Monosomy 3 is observed in 50% of uveal 
melanoma, and 70% of patients with monosomy 3 die of 
metastases within four years after the initial diagnosis, 
whereas patients with disomy 3 (normal chromosome 3) 
rarely develop metastatic uveal melanoma [35]. Recently, 
researchers have identified mutations in BAP1 gene, 
located on chromosome 3, and this gene seems to play a 
major role in tumor progression in uveal melanoma [36]. 
Also, a gene expression profiling (GEP) assay demon-
strated that class 2 is the most accurate poor prognostic 
marker for patients with uveal melanoma [37, 38]. A pre-
vious PDX study reported that tumors from patients hav-
ing monosomy 3 or class 2 in GEP were relatively easy to 
engraft into mice [39]. However, in our study, monosomy 
3 and BAP1 mutations did not clearly correlate with the 
success rates of engraftment and serial passage. On the 
other hand, high expression of Ki67 contributed to the 
success of serial passages. Ki67 positivity is reported to 
be strongly associated with class 2 in GEP and mono-
somy 3 [40]. The expression of Ki67 was marginally cor-
related with monosomy 3 in our study (data not shown, 
p = 0.0556). Ki67 has an important role in cell prolifera-
tion and tumor progression in uveal melanoma. The rela-
tive expression level of Ki67 might, therefore, be a useful 
parameter for predicting the establishment of a given 
uveal melanoma tumor in our PDX platform.
Page 14 of 19Kageyama et al. J Transl Med  (2017) 15:145 
A major drawback of orthotopic hepatic PDX models is 
difficulty in measuring tumor growth. In this regard, we 
confirmed that CT scan is exceedingly helpful in evaluat-
ing tumor growth in the liver. The use of commercially 
available CT contrast agent allows detection and visuali-
zation of interior liver tumors in live animals. The con-
trast agent specifically enhances normal mouse liver 
parenchyma on the CT so that it is easy to recognize the 
unenhanced site as the tumor [41]. It also detects small 
tumors less than 1 mm, which arise as daughter nodules 
around the main tumors. This imaging approach will be 
highly beneficial for testing new agents for cancer treat-
ment by accurately measuring tumor size, which is essen-
tial in human clinical trials.
Our model has some limitations that we expect to 
address in future work. First, xenograft tumors are sur-
rounded by mouse tissue, even though they are ortho-
topically implanted. Patient-derived xenograft tumors are 
thus destined to be fostered by mouse vessels and tissues. 
Liver metastasis mouse models using human uveal mela-
noma cell lines contain mouse-derived vessels within 
the tumor [42]. Since growth factors, cytokines, and 
chemokines could have species-specificity, PDX mouse 
models might not be the best model to investigate inter-
actions between the tumor and its microenvironment. In 
this regard, a chimeric mouse model with a humanized 
liver would provide a better human tissue microenviron-
ment for the implanted human tumors to the liver [43]. 
Another major challenge to the PDX approach is the lack 
of tumor-immune system interactions. A humanized 
immune system mouse, such as a hu-BLT and hu-PBMC 
mouse, might be preferable for some aspects of future 
PDX research [44, 45].
Conclusions
In conclusion, orthotopic PDX models can be developed 
from hepatic metastases of uveal melanoma patients with 
the liver pocket method. With CT scan imaging tech-
nology, development and growth of hepatic tumors in 
NSG mice can be easily monitored. This is considered 
to be much more close to the clinical situation of actual 
patients, compared to ectopic transplantation of tumor 
specimens to subcutaneous site devoid of liver micro-
environment. Pre-clinical investigation of specific signal 
blockades using this orthotopic PDX model should be 
warranted.
Methods
Regulatory and ethical considerations
Patients provided written consent allowing the use of 
tissue samples for this research, according to an Institu-
tional Review Board-approved protocol. The animal study 
was approved by the Institutional Animal Care and Use 
Committee of Thomas Jefferson University and adhered to 
the recommendations in the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals.
Metastatic uveal melanoma cell lines
TJU-UM001 and TJU-UM004 cell lines were established 
in our laboratory at Thomas Jefferson University and 
authenticated by the DDC Medical (Fairfield, OH, USA). 
They are derived from a liver metastasis and an orbital 
metastasis of human uveal melanoma, respectively. Both 
UM001 and UM004 cells harbor the Q209L mutation as 
determined by Sanger DNA sequencing, as previously 
described [46, 47]. UM001 cells were cultured in RPMI 
1640 medium supplemented with 10% heat-inactivated 
FBS, 10% non-essential amino acids, 2 mM l-glutamine, 
10  mM HEPES buffer, 50  IU/ml penicillin and 50  mg/
ml streptomycin. UM004 cells were cultured in MEM 
medium containing 10% heat-inactivated FBS, 50  IU/ml 
penicillin and 50 mg/ml streptomycin.
Patient-derived liver metastatic uveal melanoma samples
Tumor specimens were obtained after surgery or biopsy 
from liver metastatic uveal melanoma patients. Tumor 
masses were washed with sterile PBS and were cut 
into 1  mm cubes for implantation into the mouse liver 
(Fig.  6a). Procurement of tumor specimens and tumor 
implantation were performed within 2 h.
Animals
Eight-week-old male and female NSG mice (Jackson 
Laboratory, Bar Harbor, ME, USA) were used for tumor 
injection or implantation into the liver or a subcutaneous 
site. For the tumor injection or implantation, each mouse 
was anesthetized with 3% Isoflurane for induction and 
2% for maintenance.
Laparotomy
Mice were placed on a heating pad in the supine position. 
A 1 cm skin incision was made in the left subcostal area, 
followed by a 1 cm incision in the peritoneum to expose 
the liver. Using a cotton swab, the left lobe of the liver 
was moved outside the body and placed on a nonwoven 
absorbent fabric sheet for the injection or implantation. 
After the injection or surgical implantation, the liver was 
returned within the body, and the abdominal incision 
was closed in 2 layers with 5-0 polydioxanone absorbable 
thread (AD Surgical, Sunnyvale, CA, USA).
Needle tumor injection into the liver and subcutaneous 
site
UM001 cells (1 ×  106) in 20 μl of RPMI 1640 or UM004 
cells (1 ×  106) in 20 μl of MEM were mixed with Matrigel 
(BD Biosciences, Bedford, MA, USA) (mixing ratio of 
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2:1) and injected directly under the surface of the left 
lobe of the liver with a Hamilton syringe using a 27 G 
needle (Hamilton Company, Reno, NV, USA) [42]. For 
subcutaneous injection, UM001 cells or UM004 cells 
(1.0–10.0 × 106) were injected with a 25 g needle into a 
subcutaneous site in the hind limb. The subcutaneously 
injected tumors were measured up to 12 weeks by caliper.
Surgical orthotopic implantation using liver pocket 
method
The left lobe of the mouse liver was exposed by laparot-
omy (Fig. 6b, c). The liver was incised using a No. 11 sharp 
scalpel (AD Surgical, Sunnyvale, CA, USA) horizontally 
in parallel with the surface of the liver to form a pocket 
in the parenchyma without cutting any major vessels 
(Fig.  6d). A tumor piece was implanted into the pocket 
(Fig. 6e). The incision site was then sealed with absorbable 
hemostatic material (SURGICEL, Johnson and Johnson, 
New Brunswick, NJ, USA) to curtail bleeding (Fig.  6f ) 
[48]. The liver was returned to its original position after 
confirming hemostasis from the liver (Fig. 6g).
Surgical implantation at subcutaneous sites
A 3-mm incision was made in the skin of the hind limb. 
Scissors were inserted into the subcutaneous space to 
create a pocket. A tumor piece was inserted into this sub-
cutaneous pocket, and then the incision was closed with 
5-0 polydioxanone absorbable thread.
CT imaging and contrast agent
Micro-CT scan (Inveon Micro-CT, Siemens, Germany) 
was performed 4 h after injection of contrast agent. The 
contrast agent (ExiTron nano 12000, Miltenyi Biotec, 
Germany) is an alkaline earth-based nanoparticulate 
contrast agent for mouse liver CT imaging [41]. Upon 
intravenous injection, the agent is taken up by cells of 
the reticuloendothelial system, including macrophages 
within the liver, termed Kupffer cells. Mice were injected 
with 100  µl of agent (per mouse, 25–30  g body weight) 
via a lateral tail vein.
Collection of tumor masses from mice
UM001 tumors, UM004 tumors, or patient-derived 
xenograft tumor masses were collected from the mice 
at the scheduled time of sacrifice. The tumor vol-
ume was calculated using the following formula: 
Volume =
(
W
2
× L
)
/2 , with W being the shortest diam-
eter and L being the longest diameter. Resected tumors 
were washed with sterile PBS. A portion of the tumor 
was cut into 1 mm cubes for implantation into the liver of 
recipient mice. The remaining tumor was used for analy-
ses of tumor characteristics and cryopreservation.
Cryopreservation and thawing procedure
Tumor masses from established PDX mouse models 
were cut into 2 mm cubes and transferred to sterile cryo-
tubes containing one of 3 different cryomedia: F medium 
Fig. 6 Surgical orthotopic implantation using the liver pocket method. a Small tumor pieces to be implanted. b Liver is exposed. c Liver is moved 
outside the abdominal cavity. d Liver pocket is produced by surgical incision. e Tumor piece is inserted into the liver. f Incision is covered and bleed-
ing is halted using hemostatic materials. g Liver is returned into the abdominal cavity
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(90% fetal bovine serum/10% DMSO), D medium (70% 
DMEM/20% fetal bovine serum/10% DMSO), and 
R medium (70% RPMI/20% fetal bovine serum/10% 
DMSO). Cryotubes were placed in a freezing chamber 
containing isopropanol within a −80  °C freezer, which 
froze the samples at a rate of −1  °C/min. Frozen tumor 
specimens were transferred to liquid nitrogen storage 
the next day. For thawing, cryotubes were incubated in 
a water bath (37  °C) until melted. Thawed tumors were 
washed with sterile PBS and then cut into 1  mm cubes 
for implantation into the liver of recipient mice.
Histology and immunohistochemistry
For histopathological evaluation, H&E staining was per-
formed on paraffin-embedded tumor tissue sections. The 
degree of pigmentation of tissue samples was assessed based 
on the Collaborative Ocular Melanoma Study (COMS) clas-
sification system [49]. For immunohistochemistry, sections 
were stained with primary antibodies overnight at 4 °C. On 
the next day; sections were incubated for 30 min in Imm-
PRESS AP Reagent (Vector Laboratories, Burlingame, CA, 
USA), followed by incubating for 2–15 min in ImmPACT 
NOVA-RED (Vector Laboratories). The following primary 
antibodies were purchased from Agilent (Santa Clara, CA, 
USA): Melanosome (Clone HMB45), Melan-A, S100, and 
Ki67. All sources of specific antibodies for these markers 
and their dilution rates have been previously described [42] 
except for Ki67 (dilution rate; 1:50). Staining data for Ki67 
were quantitated by counting all positive nuclei per field of 
vision at ×400 magnification using ImageJ software (avail-
able at http://rsb.info.nih.gov/ij) [40].
Reverse phase protein arrays (RPPA)
Harvested tumor tissues were lysed and processed 
according to the MD Anderson RPPA Core Facility 
protocol (available at https://www.mdanderson.org/
education-and-research/resources-for-professionals/
scientific-resources/core-facilities-and-services/index.
html). Protein was isolated from tumor chunks, adjusted 
to 1 to 1.5 mg/ml, boiled for 5 min after the addition of 
4× SDS sample buffer, stored at −80  °C, and submitted 
to the MD Anderson RPPA Core Facility. Lysates were 
tested using a panel of 299 validated antibodies, and anal-
yses were performed on normalized data. Unsupervised 
hierarchical cluster analysis based on Pearson distance 
combined with average linkage was performed using 
MeV 4.8 (Multiple Experiment Viewer) (Dana-Farber 
Cancer Institute, Boston, MA, USA) [50].
Genomic studies detecting mutations and DNA copy 
number variants
DNA was extracted from the tumor samples with QIAmp 
DNA Mini Kit (Qiagen, Valencia, CA). Genomic libraries 
were prepared using extracted DNA and customized 
for the Truseq Amplicon Cancer Panel Kit (Illumina, 
San Diego, CA, USA). The mutational status of GNAQ, 
GNA11, BAP1, SF3B1, and E1F1AX genes was assessed 
using the Miseq sequencer (Illumina) [51]. Specific muta-
tions and primers for all of these genes are detailed in 
Additional file 7: Table S2. Genomic DNA samples were 
analyzed for reproducibility of genome-wide copy num-
ber, loss of heterozygosity, and somatic mutations using 
a single nucleotide polymorphism (SNP) microarray 
provided by the Affymetrix CytoScan HD Array plat-
form (Affymetrix, Santa Clara, CA). Data analysis was 
performed using the Chromosome Analysis Suite soft-
ware package (Affymetrix). Copy number gains and 
losses  >1  MB are reported in this analysis. Genomic 
studies were performed at Cancer Genome Core Facil-
ity of Sideny Kimmel Cancer Center at Thomas Jefferson 
University (Director, Dr. Paolo Fortina). Unsupervised 
hierarchical cluster analysis based on Euclidean distance 
combined with complete linkage was performed using 
the hclust function in R version 3.3.0 (available at http://
www.r-project.org).
Statistical analysis
Data with non-normal distributions are presented with 
median and range. The non-parametric Mann–Whitney 
U-test was performed for comparison of Ki67 expression 
levels. The Pearson correlation test was performed to 
assess consistency of two samples in RPPA analysis and 
to examine correlations between Ki67 expression and 
tumor volume. A regression line between two samples 
was generated, and the correlation coefficient (r) was cal-
culated. Fisher’s exact test was performed to identify pre-
dictive factors for the success of engraftment and serial 
passages. Groups were considered to be significantly 
different at p < 0.05. Statistical analyses were performed 
by GraphPad Prism (GraphPad Software, La Jolla, CA, 
USA).
Additional files
Additional file 1: Table S1. Results of orthotopic tumor implantation to 
the liver using hepatic tumor specimens derived from metastatic uveal 
melanoma cell lines.
Additional file 2: Figure S1. a–p: Macroscopic, histopathological, 
and radiological features of liver-implanted tumors and subcutane-
ously implanted tumors using metastatic uveal melanoma cell lines. a, i: 
Laparotomy image. b, g, j, o: Macroscopic findings for resected tumors. c, 
k: Cut surface of the tumor. d, l: Sagittal imaging on CT, Black arrows indi-
cate tumors. e, m: H&E staining, x10, Scale bar, 1 mm. f, n: Macroscopic 
findings for subcutaneously implanted sites. h, p: H&E staining, x40, Scale 
bar 500 µm. Abbreviation: SC = subcutaneous site.
Additional file 3: Figure S2. a: Representative biomarker expres-
sion patterns in donor and recipient tumors. Immunostaining with four 
antibodies as indicated. Donor sections are depicted in the columns 1 and 
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Abbreviations
PDX: patient-derived xenograft; SOI: surgical orthotopic implantation; NSG: 
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hematoxylin and eosin; CNVs: copy number variations; PDOX: patient-derived 
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Ocular Melanoma Study; SNP: single nucleotide polymorphism.
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